ArticleAdvances in hematology2022

Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma.

Shinya Ohata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.